Genital Neoplasms, Female Clinical Trial
Official title:
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.
Patients with recurrent, radiation/chemotherapy-resistant gynecological cancer carry a poor prognosis. H101 is a recombinant human type-5 adenovirus (Ad5), in which the E1B and E3 gene have been deleted. Previous studies have shown that H101 has anticancer activity and safety in some solid tumors, but has little report in gynecological oncology. In this clinical trial, 60 recurrent or refractory gynecological cancer patients will be enrolled. Based on individual conditions, all eligible patients are intra-tumor injected oncolytic viruses H101 within 5 consecutive days combined with or without radiotherapy in sequential, three weeks for a cycle (1-4 cycles totally). Simultaneously, the tumor sample, peripheral blood, and urine specimen were collected on day1 and day5. Local control rate and side effects are recorded respectively. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02182245 -
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
|
Phase 1 | |
| Completed |
NCT00121030 -
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
|
Phase 2 | |
| Completed |
NCT00191646 -
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT04679675 -
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
|
N/A | |
| Terminated |
NCT00332280 -
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05360459 -
Characterization of the Intestinal and Vaginal Microbiota in Long-term Survivors of Gynecological Cancer
|
||
| Not yet recruiting |
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02966327 -
Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer
|
N/A | |
| Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
| Completed |
NCT02609880 -
Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer
|
N/A | |
| Completed |
NCT00191607 -
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
|
Phase 3 | |
| Terminated |
NCT02499952 -
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
|
Phase 2 | |
| Terminated |
NCT01032447 -
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
|
N/A | |
| Recruiting |
NCT02781155 -
Limiting Chemotherapy Side Effects by Using Moxa
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00391664 -
Questionnaire Study for Gynecological Cancer Survivors
|
N/A | |
| Completed |
NCT00190983 -
A Trial for Patients With Advanced/Recurrent Cervical Cancer
|
Phase 2 | |
| Completed |
NCT00523432 -
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
|
Phase 1 |